- Home
- BIIB vs HUBB Comparison
BIIB vs HUBB Comparison
Compare BIIB & HUBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HUBB
- Stock Information
- Founded
- BIIB 1978
- HUBB 1888
- Country
- BIIB United States
- HUBB United States
- Employees
- BIIB N/A
- HUBB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HUBB Industrial Machinery/Components
- Sector
- BIIB Health Care
- HUBB Technology
- Exchange
- BIIB Nasdaq
- HUBB Nasdaq
- Market Cap
- BIIB 24.2B
- HUBB 23.2B
- IPO Year
- BIIB 1991
- HUBB N/A
- Fundamental
- Price
- BIIB $175.74
- HUBB $422.11
- Analyst Decision
- BIIB Buy
- HUBB Buy
- Analyst Count
- BIIB 23
- HUBB 7
- Target Price
- BIIB $176.48
- HUBB $473.86
- AVG Volume (30 Days)
- BIIB 2.0M
- HUBB 677.1K
- Earning Date
- BIIB 10-30-2025
- HUBB 10-28-2025
- Dividend Yield
- BIIB N/A
- HUBB 1.39%
- EPS Growth
- BIIB N/A
- HUBB 15.10
- EPS
- BIIB 10.97
- HUBB 15.99
- Revenue
- BIIB $10,065,900,000.00
- HUBB $5,686,200,000.00
- Revenue This Year
- BIIB $2.97
- HUBB $6.12
- Revenue Next Year
- BIIB N/A
- HUBB $7.43
- P/E Ratio
- BIIB $15.97
- HUBB $26.39
- Revenue Growth
- BIIB 4.77
- HUBB 0.82
- 52 Week Low
- BIIB $110.04
- HUBB $299.43
- 52 Week High
- BIIB $176.02
- HUBB $484.26
- Technical
- Relative Strength Index (RSI)
- BIIB 76.31
- HUBB 42.11
- Support Level
- BIIB $165.75
- HUBB $412.25
- Resistance Level
- BIIB $170.78
- HUBB $432.48
- Average True Range (ATR)
- BIIB 5.16
- HUBB 13.66
- MACD
- BIIB 1.34
- HUBB -5.55
- Stochastic Oscillator
- BIIB 98.74
- HUBB 26.54
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About HUBB Hubbell Inc
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.